ANTIHYPERTENSIVE TREATMENT AND ITS IMPLICATIONS ON LIPOPROTEIN METABOLISM
Of Patients in Care by a Hypertension and Diabetes Program in Brazil

Multiple risk factors for cardiovascular disorders, particularly hypercholesterolemia, are often present in hypertensive patients. Several studies have shown that antihypertensive drugs affect the lipid profile, increasing the risk of cardiovascular diseases. Here, it was investigated the lipoprotein metabolism alterations in a group of hypertensive patients in care by the Hypertension and Diabetes Program of a public hospital in Fortaleza-CE/Brazil. In this study, one hundred sixty nine serum samples from hypertensive patients (32-87 years old) under antihypertensive therapy were analyzed. Triglycerides, total cholesterol, cholesterol from high density lipoprotein (HDL) and from low density lipoprotein (LDL) serum levels were determined by enzymatic colorimetric method and AI and B apolipoproteins by immunoturbidimetric assay. The population enrolled was predominantly women (73.13%) and from these, 33.53% taking the monotherapy regimen, used angiotensin converting enzyme inhibitors (ACE-I). However, in combined therapy (66.47%) the most used drugs were the diuretics, especially in prescriptions associated to ACE-I. It was also observed that patients taking diuretics in monotherapy regimen showed significant effects in their serum lipid concentrations of lipids, in contrast with individuals taking combined therapy, which had no expressive alterations in their lipid profile. Theses results suggest that the antihypertensive therapy must be associated to a lipid monitoring process.

SUMMARY

Multiple risk factors for cardiovascular disorders, particularly hypercholesterolemia, are often present in hypertensive patients. Several studies have shown that antihypertensive drugs affect the lipid profile, increasing the risk of cardiovascular diseases. Here, it was investigated the lipoprotein metabolism alterations in a group of hypertensive patients in care by the Hypertension and Diabetes Program of a public hospital in Fortaleza-CE/ Brazil. In this study, one hundred sixty nine serum samples from hypertensive patients (32-87 years old) under antihypertensive therapy were analyzed. Triglycerides, total cholesterol, cholesterol from high density lipoprotein (HDL) and from low density lipoprotein (LDL) serum levels were determined by enzymatic colorimetric method and AI and B apolipoproteins by immunoturbidimetric assay. The population enrolled was predominantly women (73.13%) and from these, 33.53% taking the monotherapy regimen, used angiotensin converting enzyme inhibitors (ACE-I). However, in combined therapy (66.47%) the most used drugs were the diuretics, especially in prescriptions associated to ACE-I. It was also observed that patients taking diuretics in monotherapy regimen showed significant effects in their serum lipid concentrations of lipids, in contrast with individuals taking combined therapy, which had no expressive alterations in their lipid profile. Theses results suggest that the antihypertensive therapy must be associated to a lipid monitoring process.
uso de monoterapia com inibidor da enzima conversora de angiotensina (ACE-I). Entretanto, em terapia combinada (66.47%), a droga mais utilizada foi o diurético, especialmente quando associado ao ACE-I. Foi ainda observado que pacientes fazendo uso de diuréticos em regime monoterápico mostraram efeitos significativos nas suas concentrações de lípidos séricos, em oposição aos que faziam terapia combinada que não apresentaram alterações expressivas em seus perfis lipídicos. Esses resultados sugerem que a terapia antihipertensiva deve ser associada a processos de monitorização lipídico.

INTRODUCTION

Hypertension is considered one of the most important causes of premature death all around the world. This pathogenesis is being frequently associated with multiple metabolic disorders, especially hypercholesterolemia and insulin resistance, as a consequence of the reduction in the sensibility to glucose, which has been implicated in the pathogenesis of essential hypertension. Patients with concurrent hypertension and dyslipidemia are at high risk of cardiovascular disease and recent evidences suggest a relationship between hypertension and dyslipidemia, characterized, in most circumstances, by low serum levels of the high density lipoprotein (HDL), and high levels of triglycerides and low density lipoprotein (LDL).

The principal aim of the antihypertensive therapy is the reduction in atherosclerosis complications. However, some studies have demonstrated that, even significantly lowering the blood pressure, the cardiovascular events are still considerably present. Several classes of drugs are available for the hypertension treatment, but some of them such as diuretics and β-receptors blockers, adversely affect the lipoprotein profile. This effect seems to occur via insulin resistance, leading to dyslipidemia. The metabolic alterations, however, are reversible after the treatment disruption.

In this study, it was investigated the disturbances in the lipoprotein metabolism in hypertensive patients in care by the Hypertension and Diabetes Program of a public hospital in Fortaleza-CE/Brazil, under antihypertensive therapy.

MATERIALS AND METHODS

The study was conducted with 169 patients, aging between 32 and 87 years old via application of a questionnaire, inquiring about: medicine, blood pressure, life style, body mass index (BMI) and familiar history. The individuals included had systolic pressure equal or superior to 140 mmHg and/or diastolic pressure equal or superior to 90 mmHg, taking or not antihypertensive therapy. Patients were separated into two groups, according to the therapy regimen used. The monotherapy group included patients using a single antihypertensive drug, and the combined therapy group was composed by patients taking two or more antihypertensive agents for at least three months. Evaluating the influence of diuretics and beta-blockers in the lipid metabolism, patients taking ACE-I in a monotherapy regimen were used as control, since it is known that these antihypertensive agents do not affect the lipid profile. Lipoprotein and glucose levels were monitored by biochemistry analysis. Blood samples were collected after 12 hour of fastening for determining serum levels of glucose, triglycerides (TG), total cholesterol (TC) and the fractions HDL and LDL by enzymatic colorimetric methods. The apoliproteins AI and B were analyzed by immunoturbidimetric assay (Biotécnica) and dyslipidemias were classified into three groups: hypertryglicidemia, hypercholesterolemia or hetergeneous dyslipidemia, according to the border values for triglycerides (150 mg/dL) and total cholesterol (200 mg/dL).

Patients in treatment with the following medicine: lipid lowering, retinoic acid derivatives, tamoxifen, androgens, estrogens, fish oil or cyclosporine, and also with fasting serum glucose concentration > 126 mg/dL, or with hepatic and/or renal and thyroid dysfunctions, were excluded from the study.

The statistical analysis was done using the Epi info 6.04 program. For comparisons between means, Analysis of Variance (ANOVA), followed by Bonferroni, Student t test unpaired, Mann-Whitney or Kruskal Wallis were used when appropriated. Qui-square ($\chi^2$) test and Fisher’s exact
test were chosen for comparisons between proportions. Values were expressed as mean ± SD and also in percentage. Median values were used for high amplitude data, as triglycerides measurements. Data were considered to be significant at $p < 0.05$.

RESULTS

| Table 1 – Distribution of risk factors by sex of hypertensive
| Baseline characteristics | Female (%) | Male (%) | $p$
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage (%)</td>
<td>73.13</td>
<td>26.87</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Age (Years)</td>
<td>57.29 ± 11.65</td>
<td>63.72 ± 9.13</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Blood Pressure (mmHg)</td>
<td></td>
<td></td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Systolic</td>
<td>144.59 ± 15.07</td>
<td>146.11 ± 14.39</td>
<td></td>
</tr>
<tr>
<td>Diastolic</td>
<td>90.61 ± 9.5</td>
<td>89.58 ± 11.11</td>
<td></td>
</tr>
<tr>
<td>BMI (Kg/m²)</td>
<td>28.5 ± 4.08</td>
<td>29.01 ± 3.72</td>
<td></td>
</tr>
<tr>
<td>Fasting glucose (mg/DL)</td>
<td>89.79 ± 11.86</td>
<td>90.29 ± 11.37</td>
<td></td>
</tr>
</tbody>
</table>

BMI = body mass index

Table 1 shows the prevalence of women (72.6%) in the study and that the age of male individuals was proportionally significantly higher compared to the women studied. It was not observed significant differences in the diastolic or systolic pressures, neither in the fasting serum glucose concentration, nor in the body mass index (BMI) between male and female. However, all patients were overweight.

| Table 2 – Prescriptions of antihypertensive agents in mono- or combined therapy. |
|----------------------------------|------------------------|-----------------------|--------------|
| Drugs                           | (%) prescribed drugs (%) | Monotherapy (n=55) | Combined therapy (n=113) | $p$ |
| Diuretics*                      | 114 (67.5)             | 13                     | 23.6         | 101 | 89.4* | < 0.05 |
| ACE-I*                          | 87 (51.5)              | 21                     | 38.2         | 66  | 58.4* | < 0.05 |
| Beta-blockers *                 | 49 (29.0)              | 13                     | 23.6         | 36  | 31.8  | 0.26  |
| CCB**                           | 21 (12.4)              | 3                      | 5.5          | 18  | 15.9  | 0.12  |
| CAA **                          | 18 (10.7)              | 5                      | 9.1          | 13  | 11.5  | 0.79  |

Statistic Tests = *Qui-quadrado ($\chi^2$) Thiazide diuretics = 60.85; $\chi^2$ β-blockers = 1.26; $\chi^2$ ACE-I = 7.19. ** Fisher’s exact test. ACE-I = angiotensin converting enzyme inhibitors; CCB = calcium channel blockers; CAA = Centrally Acting Agents. # Number of prescriptions of each antihypertensive agent at any therapeutic regimen.

The prevalence of drugs and the therapy regimen used in the study are shown in table 2, demonstrating that combined therapy was applied to 66.1 % of patients and monotherapy regimen in to 33.9 % of patients. Diuretics (67.5 %), ACE-I (51.5 %) and beta-blockers (29%) were the most prescribed drugs. It can be was also observed that in the combined therapy the diuretics were the most prescribed medicine, being 36 % of them associated to ACE-I, and in the monotherapy regimen ACE-I was the principal group of drug of choice. Additionally, the study focused that only 14.9 % of hypertensive patients presented controlled levels of blood pressure (inferior to 140/90 mmHg), and being its majority was due to the use of monotherapy regimen in comparison to the combined therapy (Figure 1).

The lipid profile analysis pointed to the combined dyslipidemias the prevalent disturbance. The positive high correlation between total cholesterol and LDL was observed in all groups ($0.72 < r < 0.94$), mainly in the hypercholesterolemic individuals, while the higher serum levels of triglycerides, associated to low level of HDL, showed prevalence among the hypertrygliceridemic patients.

In the lipid profile analysis during monotherapy the three most prescribed therapeutic agents were studied: thiazide diuretics, β–blockers and ACE-I. Patients treated with diuretics, in the monotherapy regimen, presented significant alterations in the lipoprotein metabolism, including total cholesterol, triglycerides and LDL, and also in apolipoprotein B, compared to those taking ACE-I. The group of patients using beta-blockers did not show significant alterations in their lipid profile, compared to the control group (ACE-I) – Figure 2. Additionally, in this investigation it was not observed significant alterations in the serum concentrations of HDL and apolipoprotein AI at any group studied.

Furthermore, among patients using associated therapy, it was not noticed significant differences in the lipid or apolipoproteins AI and B metabolism, although these patients have shown important alterations in these parameters (Figure 3).

DISCUSSION

The prevalence of female patients in the population studied is in accordance to the results obtained by Lunet and Barros18, which highlights the women’s interest for searching the health service. The low prevalence of some risk factors such as stroke, cerebral vascular accident and diabetes, seems to occur due to the search of individuals with these
complications for secondary attention centers by individuals with these complications.

The high positive correlation between total cholesterol and LDL, observed in different types of dyslipidemia, may be responsible for the intensification in the development of cardiac atherosclerosis diseases. Several lines of evidence, like animal studies, prospective epidemiologic studies, genetic forms of hypercholesterolemia, and controlled clinical trials, indicate that LDL is the major atherogenic lipoprotein\(^{19}\).

Contrary, the serum levels of HDL and triglycerides seem to show an inverse correlation. This involves an increased expression of the cholesterol ester tranferase protein (CETP), and deficiency in hepatic lipases and apolipoprotein A\(_I\)\(^{20}\). The HDL serum levels and the increased risk of CAD shows strong negative correlation, while the correlation between triglycerides and CAD is highly positive\(^{21}\).

The preference in the choice of the combined therapy in comparison to the monotherapy, observed in this study, follows the recommendation of the VII Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure\(^ {22}\). However, other studies have promised the use of monotherapy\(^ {16, 23, 24}\).

Furthermore, diuretics showed to be the most prescribed drug in this study, similar to other investigations\(^ {25}\), although some studies shows the prevalence of ACE-I\(^ {23, 24}\). These opposing results could be due to differences in the

![Fig 1 – Blood pressure control in mono- or combined therapy. Statistic Test = Qui-quadrado](image)

![Fig 2 – Lipid and apolipoproteins AI and B profile in hypertensive patients taking monotherapy. Mean ± SD. Statistic tests= Student t test and Kruskal Wallis. # Diuretics versus ACE-I – Statistic F (1.24): CT= 4.4; TG = 4.94; LDL= 5.27; apoB= 8.84. ACE-I = angiotensin converting enzyme inhibitors; CT = total cholesterol, TG = tryglicerides, LDL = low-density lipoprotein cholesterol; HDL= high-density lipoprotein cholesterol; Apo AI = apolipoprotein AI, Apo B= apolipoprotein B.](image)
therapeutic regimens applied, since in our study the combined therapy was the regimen of choice.

Amongst the drugs used in the monotherapy regimen, the most prescribed drug was the ACE-I, which shows good tolerance by patients as the initial treatment of hypertension. In line with this, Esposti et al. observed that some Italian primary care centers prescribe mostly ACE-I as the initial antihypertensive treatment, especially for diabetics patients.

Hypertension remains uncontrolled in the majority of affected patients despite treatment. Comparing the two groups of patients taking monotherapy or combined therapy, only 23.2% of the former and 10.81% of the latter, presented controlled blood pressure, showing an insufficient response to treatment. This inadequate hypertension control probably had occurred by the low buying power of the population studied. This make difficult the adoption of a modified lifestyle by the population analyzed, which could reduce their clinical response to the antihypertensive treatment. In the United States, only 24% of hypertensive adults from 18 to 74 years old of age have their hypertension adequately controlled, and among patients being treated, only 55% achieve adequate blood pressure control. Additionally, the incidence of controlled hypertension is lower in men than women and those aged above 75 years.

The effect of thiazide diuretics and β-blockers agents upon the elevation of serum lipids has been intensively discussed, and the diminished sensibility to insulin is considered to be the mechanism responsible for the worsen of dyslipidemia. However, the validation of the use of β-blockers and diuretics in the hypertension treatment has been corroborated both by important American and European clinical trials, reducing with efficacy the morbidity and mortality caused by cardiovascular disorders.

The described lipid alterations observed in hypertensive individuals under treatment with diuretics may be one important factor responsible by its choice in combined therapy, since the adverse effects in the lipid metabolism occur mainly in patients taking elevated doses of these drugs. In relation to the use of β-blocker agents, not only in association to other antihypertensive drugs, but especially the preference for selective β1 seems to play an important role in the reduction of the side effects related to the lipid profile promoted by these agents.

The antihypertensive treatment with β-blockers or diuretics is recognized to reduce mortality caused by cardiovascular disorders. Those differences can be explained by the impact degree caused by the presence of concomitant cardiovascular risk factors, such as dyslipidemia, glucose intolerance, diabetes or cerebrovascular accident, which contributes to the reduction in the effectiveness of the blood pressure control and in the therapeutic optimization.
CONCLUSION

The mechanisms involved in the antihypertensive effects upon protein metabolism and how they influence clinical responses still need more investigation. In fact, the evaluation of cardiovascular risks in hypertensive patients must involve serum lipid monitoring, especially when these individuals are under antihypertensive therapy with thiazide diuretics in order to ameliorate the clinical response and prevent additional risks of atherosclerosis disorders.

Conflito de interesses:
Os autores declararam não ter nenhum conflito de interesses relativa-\n\mamente ao presente artigo.

Fontes de financiamento:
Não existiram fontes externas de financiamento para a realização
da presente pesquisa.

REFERENCES

1. EZZATI M, LOPEZ AD, RODGERS A et al: Selected major risk
determinants, and global and regional burden of disease.
2. ZANCHETTI A: The hypertensive patient with multiple risk
factors: is treatment really so difficult? Am J Hypertension
1997;10:223-9
3. LEWANCZUK RZ, PATY BW, TOOTH EL: Insulin resistance,
not diabetes status, determines blood pressure in obese and type 2
4. JACOB S, RETT K, HENRIKSEN EJ: Antihypertensive therapy
and insulin sensitivity: do we have to redefine the role of β-block-\n\ing agents? Am J Hypertens 1998;11:1258-65
5. MACDONALD TM, MORANT SV, MOZZAFARI E: Treatment
patterns of hypertension and dyslipidemia in hypertensive pa-\ntients at higher and lower risk of cardiovascular disease in primary
6. HORIO T, MIYAZATO J, KAMIDE K, TAKIUCHI S, KAWANO
Y: Influence of low high-density lipoprotein cholesterol on left
ventricular hypertrophy and diastolic function in essential hyper-
7. KANNEL WB: The Framingham Study: Its 50-year legacy and
8. GAZIANO JM, SESSO HD, BRESLOW JL, HENNEKENS CH,
BURING JE: Relation between systemic hypertension and blood lipids
on the risk of myocardial infarction. Am J Cardiol 1999;84:768-773
9. MANFROI WC, ZAGO AJ, CAMPOS M et al: Seriam as
apolipoproteinas A e B mais eficientes do que as lipoproteínas
na investigação de risco de doença arterial coronariana obstrutiva?
Arq Bras Cardiol 1999;72:657-662
10. WALLDIUS G, JUNGERN I, HOLME I, AASTVEIT AH,
KOLAR W, STEINER H: High apolipoprotein B, low
apolipoprotein A-1, and improvement in the prediction of fatal
myocardial infarction (AMORIS study): a prospective study. Lancer
2001;358:2026-33
11. NAEGELE H, BEHNKE B, GEBHARDT A, STROHBECK M:
Effects of antihypertensive drugs on cholesterol metabolism of
human mononuclear leukocytes and hepatoma cells. Clin Biochem
1998;31:37-45
12. MCINNES GT: Antihypertensive drugs in combination: addi-
tive or greater than additive? J Hum Hypertens 2007;21:914-6
13. PAPADAKIS JA, GANOTAKIS ES, JAGROOP IA,
MIKHAILIDIS DP, WINDER AF: Effect of hypertension and this
treatment on lipid, lipoprotein (a), fibrinogen, and bilirubin lev-
\els in patients referred for dyslipidemia. Am J Hypertens
1999;12:673-681
1998;11:887-9
15. MIDDEKE M, RICHTER WO, SCHWANDT P et al: Nor-
malization of lipid metabolism after withdrawal from antihyper-
tensive long-term therapy woth betablockers and diuretics. Arte-
riosclerosis 1990;10:145-7
16. BERNE C, POLLARE T, LITHELL H: Effects of antihypertensives on insulin sensitivity with special reference to
17. PLAT F, SAINI R: Management of Hypertension: The role of
18. LUNET N, BARROS H: Diferenças entre sexos no tratamento
da hipertensão arterial: um estudo comunitário no porto. Rev Port
Cardiol 2002;21:7-19
National Cholesterol Guidelines. Am J Cardiol 2002;90:11-21
20. STEIN O, STEIN Y: Atheroprotective mechanism of HDL.
Atherosclerosis 1999;144:285-301
21. BRITES FD, BONAVITA CD, DE GESITRE C et al: Altera-
tions in the steps of reverse cholesterol transport in male patients
with primary hypertriglyceridemia and low HDL-cholesterol lev-
s. Atherosclerosis 2000;152:181-192
22. The seventh report of the joint national committee on pre-
vention, detection, evaluation and treatment of high blood pressure
(JNC 7). Bethesda (MD): US Department of Health and Hu-
man Services, National Institutes of Health; May 2003
23. AKASHI D, ISSA FK, PEREIRA AC et al: Tratamento Anti-
hipertensivo. Prescrição e custo de medicamentos. Pesquisa em
hospital terciário. Arq Bras Cardiol 1998;71:55-7
24. OJEDA MA, CRENNA A, MORALES S, ESPÍNDOLA JH:
Estudio de utilización de fármacos antihipertensivos en la seguridad
social del N.E.A. Comunicaciones Científicas e Tecnológicas
2002;34:1347-57
25. MENDELSON G, NESS J, ARONOW WS: Drug treatment of
hypertension in older persons in an academic hospital-based geri-
26. ESPOSTI LD, ESPOSTI ED, VALPIANI G et al: A retrospec-
tive, population-based analysis of persistence with antihyper-
tensive drug therapy in primary care practice in Italy. Clin Ther
2002;24:1347-57
27. SPRANGER CB, RIES AJ, BERGE CA, RADFORD NB, VIC-
TOR RG: Identifying gaps between guidelines and clinical practice
in the evaluation and treatment of patients with hypertension.
Am J Med 2004;117:14-8
of discontinuation of new courses of antihypertensive medica-
29. KOHLMAN-TRIGOBOFF D: Hypertension management in
the evaluation of cardiovascular risks in hypertensive
patients must involve serum lipid monitoring, especially when these individuals are under antihypertensive therapy with thiazide diuretics in order to ameliorate the clinical response and prevent additional risks of atherosclerosis disorders.
hypertension in the general population of the United States. Arch Intern Med 2002;162:1051-8
34. LAFFER CL, ELIOVICH F: Suboptimal outcome of management of metabolic cardiovascular risk factors in hispanic patients with essential hypertension. Hypertension 1995;26:1079-84